---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000116"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:55:17.987186+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics provides pipeline update; cash at $127M, tovecimig data Q1 2025

## Summary
- Estimated $127M cash at YE 2024; cash runway expected into Q1 2027.
- Top-line Phase 2/3 data for tovecimig (CTX-009) in BTC expected end of Q1 2025.
- New drug candidate CTX-10726 (PD-1 x VEGF-A bispecific) advancing; IND submission targeted by YE 2025.
- Third dosing cohort fully enrolled for CTX-8371 Phase 1; preliminary data H2 2025.
- Two Phase 2 biomarker trials planned for mid-2025: tovecimig in DLL4+ CRC and CTX-471 in NCAM/CD56+ tumors.

## SEC filing metadata
- accession: 0001171843-25-000116
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/0001171843-25-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/f8k_010725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000116
- JSON: https://secwatch.observer/filing/0001171843-25-000116.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.